# Bio-Rad Laboratories share price today (Bio-Rad Laboratories, Inc., BIO)

> Bio-Rad Laboratories, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BIO · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/bio

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: $374.91 (+17.3% in a year)
- P/E: 45.4× (higher than 77% of the last 1 year)
- Revenue (Jun 2026): $651 M (−0.1% on a year ago)
- Profit (Jun 2026): $371 M (+16.9% on a year ago)
- Operating margin: 11.2% (−0.6 points on a year ago)
- ROE: 10%, FY25
- ROIC: 2.5%, against a 9.1% cost of capital: −6.6 points

Biggest thing to watch: the P/E is higher than 77% of its own history, so the multiple has already done part of the work. ## What is the Bio-Rad Laboratories share price today? Bio-Rad Laboratories, Inc.'s share price was $374.91 at the close on 3 November 2026. It has been rising for 20 weeks. That is 19.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $248 and $388, and at that close it sat 91% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 16 weeks in a row. Over the last 10 years the share price moved +161% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Bio-Rad Laboratories pay? Bio-Rad Laboratories, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Bio-Rad Laboratories on? Bio-Rad Laboratories is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Bio-Rad Laboratories profitable? Bio-Rad Laboratories, Inc. earned $371 M of net profit in the Jun 2026 quarter, +16.9% on the same quarter a year earlier. Full-year FY25 profit was $760 M. Over 4 years profit has grown −35.0% a year on average. That is 57.1% of the quarter's revenue. The same quarter a year earlier earned $318 M. 4 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed −0.1% on a year earlier and the margin moved −0.6 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −353.0% and revenue +1.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Bio-Rad Laboratories make, and is it growing? Bio-Rad Laboratories, Inc. reported $651 M of revenue in the Jun 2026 quarter, −0.1% on the same quarter a year earlier. Over 4 years it has grown −3.0% a year on average. The last full year, FY25, came in at $2.6 B. The last four reported quarters add to $2.6 B. FY25 revenue was $2.6 B, +0.7% on the year before. Recent pace: the last four quarters grew +1.4% on average, against −3.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.4%, against +0.5% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Bio-Rad Laboratories keep? Bio-Rad Laboratories, Inc.'s operating margin was 11.2% in the Jun 2026 quarter, 0.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between 10.3% and 19.3%. The latest quarter is within that range. Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed +0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Bio-Rad Laboratories' profit turning into cash? Over the last 2 years, 24% of Bio-Rad Laboratories, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $532 M of operating cash against $760 M of profit. After $158 M of spending on assets, $375 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Bio-Rad Laboratories' cash go? Bio-Rad Laboratories, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $480 M on assets over the last 3 years. Averaged over those years that is 6.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $480 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Bio-Rad Laboratories' P/E ratio, and how does it compare with its own history? Bio-Rad Laboratories, Inc.'s P/E is 45.4×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 27.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bio-Rad Laboratories business getting better or worse? Bio-Rad Laboratories, Inc.'s business is turning around. Profit growth has swung from −100.0% at its low to +16.9%, improving for 2 quarters in a row (from single-quarter figures), with ROE rising at 10.2%. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Bio-Rad Laboratories earn on its capital? Bio-Rad Laboratories, Inc. earned a ROE of 10% in FY25. That is up from a low of −38% in FY22. Its return on capital used (ROIC) is 6.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 29.4% net margin and 0.24× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 29.4% net margin × 0.24× asset turnover × 1.42× leverage (assets divided by equity) ≈ 10.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 2.5% − 9.1% = −6.6 percentage points. The 9.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Bio-Rad Laboratories have too much debt? Bio-Rad Laboratories, Inc. has total debt of $1.4 B against shareholder equity of $7.2 B as of Jun 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.19 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Bio-Rad Laboratories shareholding pattern? 5.1% of Bio-Rad Laboratories, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Bio-Rad Laboratories from balance-sheet trouble? For Bio-Rad Laboratories, Inc., the Z-score is 3.19. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.19 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Bio-Rad Laboratories rank in its industry? 42.5 out of 100, rank 23 of 30 in Medical Devices, with 71% of the evidence available. Bio-Rad Laboratories, Inc. scores 42.5 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 23. Relative strength against the index is 14.4%, and revenue and profit growth are weak. The four parts add up to the total exactly: 9.8 + 7 + 9 + 16.7 = 42.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bio-Rad Laboratories compared with? Bio-Rad Laboratories ranks 23 of 30 Medical Devices companies on the 4-Factor Sector Score, with 42.5 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · losing its lead · Most evidence points up · 81% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.6/20 · Lead over its industry 2.6% · Lead over S&P 500 8.7% · 1 year 50.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11.6 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · basing · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 3.3/20 · Lead over its industry -15.4% · Lead over S&P 500 -10.3% · 1 year -5.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 3.3 = 63.7 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -5.1%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · quiet · Evidence leans up · 81% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.8/20 · Lead over its industry -38.8% · Lead over S&P 500 -35.7% · 1 year -56.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.8 = 61.7 · What this means: Earnings are strong; relative strength in its sector is -38.8% and the one-year return is -56.5%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.7/20 · Lead over its industry 36.9% · Lead over S&P 500 44.6% · 1 year 76% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.7 = 59.1 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) PODD · turning · Evidence leans up · 71% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -31% · Lead over S&P 500 -27.5% · 1 year -51.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.5 = 58.5 · What this means: Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · basing · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 4.8/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.7% · 1 year -12.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 4.8 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) GKOS · leader · Evidence leans up · 64% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.7/20 · Lead over its industry 53.6% · Lead over S&P 500 62.8% · 1 year 177.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.7 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Medtronic plc](https://www.sectoralpha.in/us/stocks/mdt) MDT · breaking out · Evidence leans up · 85% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.8/20 · Lead over its industry -1.7% · Lead over S&P 500 3.9% · 1 year 7.2% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · basing · Evidence leans up · 81% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 7.3/20 · Lead over its industry -10.1% · Lead over S&P 500 -4.9% · 1 year -12.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 7.3 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 14.6% · Profit -75.8% · Operating margin change 1.7 points · 83% evidence Capital efficiency 18.6/25 · ROCE 14.8% · Operating margin 29.8% · 76% evidence Valuation 3.9/20 · P/E 51.8× · PEG 5.03 · 65% evidence Relative strength 13.2/20 · Lead over its industry 0.1% · Lead over S&P 500 6.2% · 1 year 14.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.1 + 18.6 + 3.9 + 13.2 = 53.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) PHG · turning · Evidence leans up · 71% evidence 52.3 out of 100 Growth Capital Valuation Relative
12. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · quiet · Evidence leans up · 81% evidence 52.2 out of 100 Growth Capital Valuation Relative
13. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 50.8 out of 100 Growth Capital Valuation Relative
14. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 49.4 out of 100 Growth Capital Valuation Relative
15. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 48.9 out of 100 Growth Capital Valuation Relative
16. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · losing its lead · Evidence leans down · 81% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative
18. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans down · 64% evidence 47.6 out of 100 Growth Capital Valuation Relative
19. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
20. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans down · 81% evidence 45.9 out of 100 Growth Capital Valuation Relative
21. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 44.8 out of 100 Growth Capital Valuation Relative
23. Bio-Rad Laboratories, Inc. this page BIO · leader · Evidence leans down · 71% evidence 42.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.8/35 · Revenue 1.3% · Profit -30.4% · Operating margin change -0.6 points · 83% evidence Capital efficiency 7.0/25 · ROCE 2.5% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 35.4× · PEG n/a · 15% evidence Relative strength 16.7/20 · Lead over its industry 8.1% · Lead over S&P 500 14.4% · 1 year 22.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 9.8 + 7 + 9 + 16.7 = 42.5 · What this means: Relative strength against the index is 14.4%, and revenue and profit growth are weak. 24. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.1 out of 100 Growth Capital Valuation Relative
25. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
26. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.4 out of 100 Growth Capital Valuation Relative
27. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 37.8 out of 100 Growth Capital Valuation Relative
28. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Evidence leans down · 81% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
30. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Bio-Rad Laboratories in size? Bio-Rad Laboratories is the 16th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Smith & Nephew plc, Insulet Corporation and Globus Medical, Inc. Just below it: Bruker Corporation, Haemonetics Corporation and LivaNova PLC. ### Medical Devices companies close in size

1. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) $12.5 billion
2. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) $10.7 billion
3. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) $10.7 billion
4. Bio-Rad Laboratories, Inc. $10 billion
5. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) $8.6 billion
6. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) $5.5 billion
7. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) $4.4 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Knight-Swift Transportation Holdings Inc.](https://www.sectoralpha.in/us/stocks/knx) $10 billion · Trucking
2. [Littelfuse, Inc.](https://www.sectoralpha.in/us/stocks/lfus) $10 billion · Electronic Components
3. Bio-Rad Laboratories, Inc. $10 billion
4. [Popular, Inc.](https://www.sectoralpha.in/us/stocks/bpop) $10 billion · Banks - Regional
5. [Cullen/Frost Bankers, Inc.](https://www.sectoralpha.in/us/stocks/cfr) $10 billion · Banks - Regional

## What else do people ask about Bio-Rad Laboratories? ### What is Bio-Rad Laboratories's stock price today? Bio-Rad Laboratories, Inc.'s stock price is $374.91, +17.3% over the past year. The whole company is worth $10.0 B on the market. In the last 52 weeks it traded between $248 to $388; today it is 91% of the way up from the low, 19.4% above its 200-day average (as of 3 November 2026). ### What were Bio-Rad Laboratories's latest quarterly results? Bio-Rad Laboratories, Inc. reported revenue of $651 M and net profit of $371 M for the Jun 2026 quarter. Revenue fell 0.1% and profit rose 16.9% compared with a year earlier. Earnings per share were $13.85. The operating margin was 11.2%, 0.6 percentage points lower than a year earlier (as of 3 November 2026). ### What is Bio-Rad Laboratories's market cap? Bio-Rad Laboratories, Inc.'s market capitalisation is $10.0 B at a stock price of $374.91. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bio-Rad Laboratories performing? Bio-Rad Laboratories, Inc.'s share price has been rising for 20 weeks. In its latest quarter, revenue fell 0.1% and profit rose 16.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 16 weeks running (as of 3 November 2026). ### Will Bio-Rad Laboratories's stock price go up? This page does not forecast Bio-Rad Laboratories, Inc.'s stock price. What it shows instead: the stock price is $374.91, and it has been rising for 20 weeks. Its P/E of 45.4× is higher than 77% of its own last 1 years (as of 3 November 2026). ### Where is Bio-Rad Laboratories in its business cycle? Bio-Rad Laboratories, Inc.'s FY25 operating margin was 10.3%, against a 5-year range of 10.3% to 19.3%: the low end of its own range, which is often where recoveries start. The latest quarter was 11.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bio-Rad Laboratories story? Biggest thing to watch: the P/E is higher than 77% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bio-Rad Laboratories a stock worth studying right now? What the numbers show: Bio-Rad Laboratories, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.